Jo S, Zhang H, Bean B
Mol Pharmacol. 2023; 103(4):221-229.
PMID: 36635052
PMC: 10029820.
DOI: 10.1124/molpharm.122.000593.
Bigsby S, Neapetung J, Campanucci V
Front Cell Neurosci. 2022; 16:994585.
PMID: 36467605
PMC: 9713017.
DOI: 10.3389/fncel.2022.994585.
Sun S, Sun J, Jiang W, Wang W, Ni L
Biomed Res Int. 2019; 2019:6973932.
PMID: 31032358
PMC: 6458889.
DOI: 10.1155/2019/6973932.
Chew L, Khanna R
Neuronal Signal. 2018; 2(1).
PMID: 30364788
PMC: 6197809.
DOI: 10.1042/NS20170220.
Chen C, Xu B, Shi X, Zhang M, Zhang Q, Zhang T
Br J Pharmacol. 2018; 175(20):3911-3927.
PMID: 30076786
PMC: 6151339.
DOI: 10.1111/bph.14461.
Inhibition of voltage-gated sodium channels by sumatriptan bioisosteres.
Carbonara R, Carocci A, Roussel J, Crescenzo G, Buonavoglia C, Franchini C
Front Pharmacol. 2015; 6:155.
PMID: 26257653
PMC: 4513211.
DOI: 10.3389/fphar.2015.00155.
Synthesis and analgesic effects of μ-TRTX-Hhn1b on models of inflammatory and neuropathic pain.
Liu Y, Tang J, Zhang Y, Xun X, Tang D, Peng D
Toxins (Basel). 2014; 6(8):2363-78.
PMID: 25123556
PMC: 4147587.
DOI: 10.3390/toxins6082363.
CRMP-2 peptide mediated decrease of high and low voltage-activated calcium channels, attenuation of nociceptor excitability, and anti-nociception in a model of AIDS therapy-induced painful peripheral neuropathy.
Piekarz A, Due M, Khanna M, Wang B, Ripsch M, Wang R
Mol Pain. 2012; 8:54.
PMID: 22828369
PMC: 3502107.
DOI: 10.1186/1744-8069-8-54.
The role of sodium channels in chronic pain.
Levinson S, Luo S, Henry M
Muscle Nerve. 2012; 46(2):155-65.
PMID: 22806363
PMC: 3400058.
DOI: 10.1002/mus.23314.
The tarantula toxins ProTx-II and huwentoxin-IV differentially interact with human Nav1.7 voltage sensors to inhibit channel activation and inactivation.
Xiao Y, Blumenthal K, Jackson 2nd J, Liang S, Cummins T
Mol Pharmacol. 2010; 78(6):1124-34.
PMID: 20855463
PMC: 2993464.
DOI: 10.1124/mol.110.066332.
Novel modulator of Na(V)1.1 and Na(V)1.2 Na channels in rat neuronal cells.
Mao H, Fieber L, Gawley R
ACS Med Chem Lett. 2010; 1(3):135-138.
PMID: 20607120
PMC: 2894714.
DOI: 10.1021/ml100035t.
Regulation of the spontaneous augmentation of Na(V)1.9 in mouse dorsal root ganglion neurons: effect of PKA and PKC pathways.
Kakimura J, Zheng T, Uryu N, Ogata N
Mar Drugs. 2010; 8(3):728-40.
PMID: 20411123
PMC: 2857352.
DOI: 10.3390/md8030728.
Sodium channelopathies and pain.
Lampert A, OReilly A, Reeh P, Leffler A
Pflugers Arch. 2010; 460(2):249-63.
PMID: 20101409
DOI: 10.1007/s00424-009-0779-3.
Sodium channel blockers for the treatment of neuropathic pain.
Bhattacharya A, Wickenden A, Chaplan S
Neurotherapeutics. 2009; 6(4):663-78.
PMID: 19789071
PMC: 5084288.
DOI: 10.1016/j.nurt.2009.08.001.
Structural determinants of drugs acting on the Nav1.8 channel.
Browne L, Blaney F, Yusaf S, Clare J, Wray D
J Biol Chem. 2009; 284(16):10523-36.
PMID: 19233853
PMC: 2667739.
DOI: 10.1074/jbc.M807569200.
Structurally minimized mu-conotoxin analogues as sodium channel blockers: implications for designing conopeptide-based therapeutics.
Han T, Zhang M, Walewska A, Gruszczynski P, Robertson C, Cheatham 3rd T
ChemMedChem. 2008; 4(3):406-14.
PMID: 19107760
PMC: 4074532.
DOI: 10.1002/cmdc.200800292.
The molecular basis of pain and its clinical implications in rheumatology.
Bingham B, Ajit S, Blake D, Samad T
Nat Clin Pract Rheumatol. 2008; 5(1):28-37.
PMID: 19098926
DOI: 10.1038/ncprheum0972.
Tarantula huwentoxin-IV inhibits neuronal sodium channels by binding to receptor site 4 and trapping the domain ii voltage sensor in the closed configuration.
Xiao Y, Bingham J, Zhu W, Moczydlowski E, Liang S, Cummins T
J Biol Chem. 2008; 283(40):27300-13.
PMID: 18628201
PMC: 2556013.
DOI: 10.1074/jbc.M708447200.